High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling. With these data, we generated a "cardiac safety index" to reflect the cardiotoxicities of existing TKIs. TKIs with low cardiac safety indices exhibit cardiotoxicity in patients. We also derived endothelial cells (hiPSC-ECs) and cardiac fibroblasts (hiPSC-CFs) to examine cell type-specific cardiotoxicities. Using high-throughput screening, we determined that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs, hiPSC-ECs, and hiPSC-CFs. With phosphoprotein analysis, we determined that VEGFR2/PDGFR-inhibiting TKIs led to a compensatory increase in cardioprotective insulin and insulin-like growth factor (IGF) signaling in hiPSC-CMs. Up-regulating cardioprotective signaling with exogenous insulin or IGF1 improved hiPSC-CM viability during cotreatment with cardiotoxic VEGFR2/PDGFR-inhibiting TKIs. Thus, hiPSC-CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs, and the results correlate with clinical phenotypes. This approach provides unexpected insights, as illustrated by our finding that toxicity can be alleviated via cardioprotective insulin/IGF signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“they generated a “cardiac safety index” to reflect the safety of existing tyrosine kinase inhibitors [23].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606 · cited 5×
“Chemically defined differentiation of hiPSC-CMs The hiPSCs were differentiated into hiPSC-CMs using a chemically defined protocol and maintained in medium supplemented with human albumin and ascorbic acid (8).”
BackgroundMethodInfluentialSelf-citationDemetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“This is reasonable because sorafenib and regorafenib (also known as fluoro-sorafenib) have similar molecular structures (24).”
BackgroundCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275 · cited 1×
“However, some TKIs are linked to severe cardiotoxicities including heart failure, reduced left ventricular ejection fraction, myocardial infarction, or arrhythmias (2, 3).”
BackgroundPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Cited by
Items 301–400 of 442
Mohammed, Q. K. Q., Banu, N., Police, S. R., Palakurthy, S., Thota, S., Padamati, S. P., Puligundla, K. C., Amanchi, N. R., & Kancha, R. K. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116944 · Cited by 4
Abi-Gerges, N., McMahon, C., Vargas, H., Sager, P., Chui, R., Stevens, D., Davila, J., Schaub, J. R., Wu, J. C., del Rio, C., et al. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106582 · Cited by 3
Self-citationKim, H., Choi, S., Heo, H., Cho, S. H., Lee, Y., Kim, D., Jung, K. O., & Rhee, S. (2024) · International Journal of Stem Cells · doi:10.15283/ijsc23183 · Cited by 6
Szabo, B. R., Stein, J. M., Savchenko, A. S., Hutschalik, T., Nieuwerburgh, F. V., Meese, T., Kosmidis, G., Volders, P. G. A., & Matsa, E. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1644119 · Cited by 3
Self-citationChung, C., & Tran, K. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf282 · Cited by 3
Singh, A. A., Shetty, D. K., Jacob, A. G., Bayraktar, S., & Sinha, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1349548 · Cited by 3
Kiskin, F. N., Yang, Y., Yang, H., & Zhang, J. Z. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.05.005 · Cited by 3
Schwarze‐Taufiq, T. A., Pranoto, I. K. A., Hui, K., Kinoshita, C., Yu, O., Crane, P. K., Gray, S. L., & Young, J. E. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70040 · Cited by 5
Bruyneel, A. A. N., Muser, T., Parthasarathy, V., Feyen, D. A. M., & Mercola, M. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-20047-3_2 · Cited by 3
Self-citationWan, Z., Wang, C., Luo, S., Zhu, J., He, H., & Hao, K. (2025) · Pharmaceuticals · doi:10.3390/ph18040450 · Cited by 2
“Drug specific parameters include fu, K p , H, Ka, CL, Vc, Vp, Q, k inj , hill _inj , EC 50inj , EC 50MMP , and EEC.”
InfluentialRUNX1-driven endothelial-to-mesenchymal transition contributes to remodelling in LMNA cardiomyopathy
Wu, D., Tripathi, D., Manhas, A., Noishiki, C., Liu, L., Wu, C. A., Venkateshappa, R., Zhang, H., Ren, L., Thomas, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag619 · Cited by 3
Self-citationPrediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes
Yanagida, S., & Kanda, Y. (2024) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.23-00164-3 · Cited by 2
In vitro toxicology: Next generation models and methods to improve safety evaluation
Fortin, M. C., & Szilagyi, J. T. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_120-1 · Cited by 3
Management of big data in cardio-oncology
Khadke, S., Kumar, A., Kong, Y., Dani, S. S., & Ganatra, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29829-5.00030-x · Cited by 2
Self-citationForny, C., Sube, R., & Ertel, E. A. (2018) · Journal of Visualized Experiments · doi:10.3791/58290 · Cited by 2
Sharma, A. (2020) · Science · doi:10.1126/science.aba6111 · Cited by 2
Self-citationClinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy
Feroze, R. A., Leya, J., Herron, T. J., & Hayek, S. S. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10030-7 · Cited by 3
“used iPSC-derived cardiomyocytes, endothelial cells, and cardiac fibroblasts in this role to test 21 TKIs and identified signaling pathways implicated in cardiotoxicity [122].”
MethodThree-dimensional Monolayer Stress MicroscopyPreprint
Serrano, R., Aung, A., Yeh, Y., Varghese, S., Lasheras, J. C., & del Álamo, J. C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/616987 · Cited by 2
“Furthermore, the high-throughput quantification of intracellular stresses provides great promise in the functional screening of contractile tissues for drug development (7,8).”
BackgroundSelf-citationStem cells: Stem cells in toxicology
Chaklader, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00673-4 · Cited by 2
Introducing AHA's New President: Joseph C. Wu, MD, PhD, FAHA
Kuehn, B. M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031618 · Cited by 2
Drug Discovery in Induced Pluripotent Stem Cell Models
Bourque, K., Mnasri, N., Jones-Tabah, J., Martins-Cannavino, K., & Hébert, T. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00049-9 · Cited by 1
Mazarura, G. R., & Hébert, T. E. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000958 · Cited by 2
“This screen revealed that both CMs and CFs had a similar cytotoxic profile, with sorafenib, regorafenib and ponatinib being the most cardiotoxic drugs and enabled the authors to establish a safety index for their toxicity for these compounds (Sharma et al., 2017).”
Origin and Evolution of Induced Pluripotent Stem Cells (IPSCs)
Bandyopadhyay, A. K. (2025) · Magna Scientia Advanced Biology and Pharmacy · doi:10.30574/msabp.2025.15.2.0052 · Cited by 1
Wang, Y., Li, P., Feng, T., Chen, Y., Liu, W., Ge, Q., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630053 · Cited by 1
Police, S. R., Borra, V., Tatikonda, S., Maddila, K. S. M., Mediboina, S. G., Amanchi, N. R., & Kancha, R. K. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115883 · Cited by 1
Insights and perspectives into the etiology of TKI-induced cardiotoxicity
Xu, V., Ahmed, B., Boleslav, B., Mager, D., Sparreboom, A., Sprowl, J. A., & Huang, K. M. (2026) · ASPET Discovery · doi:10.1016/j.aspetd.2026.100025 · Cited by 1
“80 The downstream signaling of IGF1R, IR, and the IGF1R/IR complex converges on a common pathway that begins with the phosphorylation of insulin receptor substrates (IRS1/2), followed by activation of the phosphoinositide 3-kinase (PI3K) and AKT pathway.”
Cell Village Captures Populational Heterogeneity of Sunitinib Cardiotoxicity
Kojic, A., Liu, Y., Belbachir, N., Tu, C., Shen, M., Caudal, A., Meharwade, T., Belbachir, M., Ford, K. A., Sallam, K., et al. (2026) · Circulation Research · doi:10.1161/circresaha.126.328704 · Cited by 1
Self-citationCrunkhorn, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.52 · Cited by 1
Induced pluripotent stem cell derived cardiac models: effects of Thymosin β4
Ziegler, T., Hinkel, R., & Kupatt, C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1473370 · Cited by 1
“were not only able to recapitulate the cardiotoxic effects of the VEGFR2/PDGFRinhibiting TKIs sorafenib, regorafenib, and ponatinib but were also able to demonstrate that treatment with insulin or IGF1 was able to alleviate the toxic effects of those drugs [60].”
BackgroundCardio-oncology: Network-Based Prediction of Cancer Therapy-Induced Cardiotoxicity
Cheng, F. (2019) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-030-16443-0_5 · Cited by 1
He, X., You, H., Gong, J., Zhang, Y., Du, J., Wang, X., Gu, S., Cao, N., & Wang, J. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.10.010 · Cited by 1
“Furthermore, hPSC-derived CMs (hCMs) are also suitable for identifying and analyzing the genetic basis and molecular mechanisms of drug-induced cardiotoxicity [ 22–24 ].”
Self-citationTranscriptomic Approaches to Cardiomyocyte–Biomaterial Interactions: A Review
Wen, Y., Yang, H., & Hong, Y. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00303 · Cited by 1
Mozneb, M., Moses, J., Arzt, M., Escopete, S. S., & Sharma, A. (2024) · Current Protocols · doi:10.1002/cpz1.70030 · Cited by 1
“If using Fluo-4 dye, this is a good time to prepare relevant buffer solutions and add the dye to samples (Sharma et al., 2017).”
InfluentialSelf-citationBelle, K. C., Kreymerman, A., Young, J. L., Vadgama, N., Ji, M. H., Randhawa, S., Caicedo, J., Wong, M. Y., Muscat, S. P., Gifford, C. A., et al. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109049 · Cited by 1
Self-citation[Leukocyte count of puerperal sows].
Mäde, D., & Wujanz, G. (1996) · PubMed · Cited by 1
Papers of note in Science Translational Medicine 9 (377)
Ferrarelli, L. K. (2017) · Science Signaling · doi:10.1126/scisignal.aam9940
OBSOLETE: Arrhythmias in Cancer and Cancer Treatment: A Review
Guha, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64167-3
OBSOLETE: Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Advancing Cardiovascular Medicine
Hong, C. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.10919-5
Kurokawa, Y. K. (2017) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7db818f
Neue onkologische Therapien und ihre kardiovaskulären Risiken: Was sollte der Kardiologe kennen?
Totzeck, M., & Rassaf, T. (2020) · Herz · doi:10.1007/s00059-020-04902-6
Gunawan, M. G. (2019) · Summit (Simon Fraser University)
Modeling the cardiovascular toxicities of anticancer therapies in the era of precision medicine
Dunkenberger, L., & Karakikes, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822231-7.00006-0
Lücker, P. B. (2018) · TSpace (University of Toronto)
Zhang, Y., Wang, M., Zhao, Q., Xing, H., Yang, X., & Wang, X. (2020) · doi:10.21203/rs.3.rs-27568/v1
Self-citationChristidi, E. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0402336
Predicting the Toxicity of Druggable Proteins to Human TissuesPreprint
Hao, Y., Thangaraj, P., & Tatonetti, N. P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.07.471637
hiPSCs for population genetics
Chen, Z., Su, S., & Cowan, C. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99892-5.00018-9 · Cited by 1
Borchert, T. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8874
Molecular mechanisms of TBX5-related conduction disorders
Rathjens, F. S. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8451
The correlation between serum leptin level and thyroid hormones in Jordanian hypothyroidism patients
Wedyan, M. A., MESLOUB, I., Qnais, E. Y., Bseiso, Y., Alqudah, A. M., HUSSEIN, E., & Ghenaimi, S. A. (2022) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.20.04556-8
Huang, J., Chen, H., Lan, S., Qin, L., Xun, Z., Han, S., Zhao, H., Ci, Y., Xu, C., Zhu, W., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-574349/v1
Arrhythmias in Cancer and Cancer Treatment: A Review
Haddad, D. N., Guha, A., Awan, F., Daoud, E. G., & Baliga, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.64167-4
A human population-based organotypic in vitro model for cardiotoxicity screening_suppl
Grimm, F. A. (2018) · ALTEX · doi:10.14573/altex.1805301s · Cited by 2
Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Advancing Cardiovascular Medicine
Zhang, C., Cadar, A. G., & Hong, C. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.10919-6
Improving three-dimensional human pluripotent cell culture efficiency via surface molecule coating
Li, Q., Pan, Y., Han, L., Yang, Y., Wu, X., & Lei, Y. (2022) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2022.1031395 · Cited by 1
“, 2015), testing drug toxicity (Matsa et al., 2016a; Matsa et al., 2016b; Burridge et al., 2016; Kodo et al., 2016; Sayed et al., 2016; Sharma et al., 2017; Magdy et al., 2018), engineering tissues, and developing cell-based therapies (Barker et al.”
BackgroundMultifaceted Role of Induced Pluripotent Stem Cells in Preclinical Cardiac Regeneration Research
Derish, I., & Cecere, R. (2023) · Springer eBooks · doi:10.1007/978-981-99-0846-2_33-1
Belle, K. C., Kreymerman, A., Vadgama, N., Ji, M. H., Randhawa, S., Caicedo, J., Wong, M. Y., Muscat, S. P., Gifford, C. A., Lee, R. T., et al. (2023) · medRxiv · doi:10.1101/2023.11.03.23297854
“The contractility image analysis, using TMRM signal derived vectorized points of movement through a time series and physiological parameter calculations were conducted, as previously described 14 .”
MethodSelf-citationInduced pluripotent stem cells for cardiovascular therapeutics: Progress and perspectives
Kizub, I. V. (2023) · Regulatory Mechanisms in Biosystems · doi:10.15421/10.15421/022366
Chou, F., & Tang, W. (2023) · Sriwijaya Journal of Internal Medicine · doi:10.59345/sjim.v1i2.77
Borgne, E. L. (2022) · theses.fr (ABES) · doi:10.70675/234a825cz3599z40edz978cz9fd5925bd0f6 · Cited by 1
Drug Development Using Human iPSC-Derived Cardiomyocytes and Future Perspectives
Kawagishi, H., Yanagida, S., & Kanda, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00078-4
Multifaceted Role of Induced Pluripotent Stem Cells in Preclinical Cardiac Regeneration Research
Derish, I., & Cecere, R. (2024) · Springer eBooks · doi:10.1007/978-981-99-7119-0_33
Sotoudeheian, M., Azarbad, R., Mirahmadi, S., Pirhayati, M., Moradi, M., & Pazoki–Toroudi, H. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010324744240916110446 · Cited by 1
Advancement of Synthetic Biology Strategies for Bioinspired Regenerative Medicine
Khoshnevisan, K., Maleki, H., & Baharifar, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_14 · Cited by 1
Heart-Derived Stromal Cells and In Vitro 3D Models in Cardiotoxicity Assessment
Sun, D., & Thankam, F. G. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_31
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944878
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944761
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610382
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944845
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944806
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944836
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944890
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944752 · Cited by 1
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944779
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944755
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944839
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944764
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610385
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944866
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944803
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944827
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944812
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944863
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944770
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944749
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944821
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944875
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944884
Novel Cellular Models of Human Myopathies
Kim, E. Y. (2018) · Knowledge@UChicago (University of Chicago) · doi:10.6082/pd7nv-72d70
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610391
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944869
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944854
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944830
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944746
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944872
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944824
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944833
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944860
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944767
Metadata
- Authors
- Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A. C., del Álamo, J. C., Wu, S. M., Moslehi, J. J., Mercola, M., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- Northwestern University (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of California San Diego (US)
- Department of Mechanical and Aerospace Engineering, University of California, San Diego, La Jolla, CA 92092, USA.
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Sharma, Arun
- Burridge, Paul W.
- Wu, Joseph C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-15
- Volume
- 9
- Issue
- 377
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5409837
- OpenAlex
- W2587938050
- Cited by
- 404
- References
- 49
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 55 · 2023: 34 · 2022: 41 · 2021: 50 · 2020: 56 · 2019: 52 · 2018: 47 · 2017: 23
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (award280979)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- tyrosine kinase inhibitors, cardiotoxicity, human induced pluripotent stem cell-derived cardiomyocytes, high-throughput screening, VEGFR-2 inhibitors, PDGFR inhibitors, endothelial cells, cardiac fibroblasts, insulin signaling, IGF-1 signaling, cardioprotection
- MeSH terms
- Fibroblasts, Humans, Insulin, Insulin-Like Growth Factor I, Models, Biological, Phosphorylation, Sarcomeres, Signal Transduction, Biomarkers, Myocytes, Cardiac, Vascular Endothelial Growth Factor Receptor-2, Protein Kinase Inhibitors, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.